{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T19:41:22Z","timestamp":1794944482287,"version":"4.9.1"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.lanepe.2024.100838","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:10:47Z","timestamp":1709251847000},"page":"100838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries"],"prefix":"10.1016","volume":"38","author":[{"given":"Vincent D.","family":"de Jager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4146-6363","authenticated-orcid":false,"given":"Wim","family":"Timens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bayle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Botling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9098-8416","authenticated-orcid":false,"given":"Luka","family":"Brcic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriela O.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libor","family":"Havel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian J.","family":"Hochmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0646-0705","authenticated-orcid":false,"given":"L\u00e9on","family":"van Kempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izidor","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Lopez-Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margreet","family":"L\u00fcchtenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Carlos","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Mohorcic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3051-2280","authenticated-orcid":false,"given":"Ale\u0161","family":"Ry\u0161ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillipe","family":"Taniere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Schuuring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthonie J.","family":"van der Wekken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lanepe.2024.100838_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100838_bib2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.annonc.2023.01.010","article-title":"European cancer mortality predictions for the year 2023 with focus on lung cancer","volume":"34","author":"Malvezzi","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.lanepe.2024.100838_bib3","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/resp.13827","article-title":"Lung cancer staging: state of the art in the era of ablative therapies and surgical segmentectomy","volume":"25","author":"Gregor","year":"2020","journal-title":"Respirology"},{"issue":"7","key":"10.1016\/j.lanepe.2024.100838_bib4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100838_bib5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.lanepe.2024.100838_bib6","doi-asserted-by":"crossref","first-page":"887","DOI":"10.21037\/tlcr.2020.04.07","article-title":"Lung cancer biomarker testing: perspective from Europe","volume":"9","author":"Thunnissen","year":"2020","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"10.1016\/j.lanepe.2024.100838_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12885-018-4023-4","article-title":"NSCLC molecular testing in Central and Eastern European countries","volume":"18","author":"Ryska","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lanepe.2024.100838_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2021.02.026","article-title":"The evolving landscape of biomarker testing for non-small cell lung cancer in Europe","volume":"154","author":"Kerr","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lanepe.2024.100838_bib9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2022.09.005","article-title":"Access and quality of biomarker testing for precision oncology in Europe","volume":"176","author":"Normanno","year":"2022","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.lanepe.2024.100838_bib10","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2023.06.011","article-title":"ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lanepe.2024.100838_bib11","doi-asserted-by":"crossref","first-page":"100839","DOI":"10.1016\/j.lanepe.2024.100839","article-title":"Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer","volume":"38","author":"de Jager","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanepe.2024.100838_bib12","doi-asserted-by":"crossref","first-page":"100840","DOI":"10.1016\/j.lanepe.2024.100840","article-title":"New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe","volume":"38","author":"Houda","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.lanepe.2024.100838_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13073-022-01041-x","article-title":"Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology","volume":"14","author":"Adib","year":"2022","journal-title":"Genome Med"},{"issue":"14","key":"10.1016\/j.lanepe.2024.100838_bib14","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.3390\/cancers13143641","article-title":"A\u00a0nationwide study on the impact of routine testing for EGFR mutations in advanced NSCLC reveals distinct survival patterns based on EGFR mutation subclasses","volume":"13","author":"Koopman","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.lanepe.2024.100838_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.lanepe.2024.100838_bib16","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.lanepe.2024.100838_bib17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ccell.2022.06.006","article-title":"Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity","volume":"40","author":"Elamin","year":"2022","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.lanepe.2024.100838_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.4761","article-title":"Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR Exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1\/2 open-label nonrandomized clinical trial","volume":"7","author":"Zhou","year":"2021","journal-title":"JAMA Oncol"},{"issue":"30","key":"10.1016\/j.lanepe.2024.100838_bib19","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.lanepe.2024.100838_bib20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/1078-0432.CCR-22-2072","article-title":"FDA approval summary: mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","volume":"29","author":"Duke","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.lanepe.2024.100838_bib21","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-22-3713","article-title":"FDA approval summary: amivantamab for the treatment of patients with non-small cell lung cancer with EGFR exon 20 insertion mutations","volume":"29","author":"Chon","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.lanepe.2024.100838_bib22","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1093\/oncolo\/oyad111","article-title":"Clinical outcomes of afatinib versus osimertinib in patients with non-small cell lung cancer with uncommon EGFR mutations: a pooled analysis","volume":"28","author":"Wang","year":"2023","journal-title":"Oncologist"},{"issue":"7878","key":"10.1016\/j.lanepe.2024.100838_bib23","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.lanepe.2024.100838_bib24","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lanepe.2024.100838_bib25","doi-asserted-by":"crossref","first-page":"100841","DOI":"10.1016\/j.lanepe.2024.100841","article-title":"Challenges and controversies in resectable non-small cell lung cancer: a clinician\u2019s perspective.","volume":"38","author":"Houda","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"10.1016\/j.lanepe.2024.100838_bib26","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/j.cllc.2021.06.011","article-title":"Actionability of on-target ALK resistance mutations in patients with non-small cell lung cancer: local experience and review of the literature","volume":"23","author":"Koopman","year":"2022","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"10.1016\/j.lanepe.2024.100838_bib27","article-title":"Real-world outcome analysis of patients with stage IV NSCLC treated with tyrosine kinase and immune checkpoint inhibitors","volume":"4","author":"Ariyasu","year":"2023","journal-title":"JTO Clin Res Rep"},{"issue":"11","key":"10.1016\/j.lanepe.2024.100838_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101191","article-title":"Will the clinical development of 4th-generation \"double mutant active\" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+NSCLC?","volume":"14","author":"Ou","year":"2021","journal-title":"Transl Oncol"},{"issue":"21","key":"10.1016\/j.lanepe.2024.100838_bib29","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.lanepe.2024.100838_bib30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanepe.2024.100838_bib31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.lungcan.2019.02.025","article-title":"CNS metastasis in ROS1+ NSCLC: an urgent call to action, to understand, and to overcome","volume":"130","author":"Ou","year":"2019","journal-title":"Lung Cancer"},{"issue":"24","key":"10.1016\/j.lanepe.2024.100838_bib32","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","article-title":"Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations","volume":"37","author":"Dankner","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.lanepe.2024.100838_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2022.09.008","article-title":"Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort","volume":"173","author":"Lim","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lanepe.2024.100838_bib34","article-title":"Clinical activity of mitogen-activated protein kinase-targeted therapies in patients with non-V600 BRAF-mutant tumors","volume":"6","author":"Dankner","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.lanepe.2024.100838_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920975613","article-title":"A\u00a0systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors","volume":"12","author":"Forsythe","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100838_bib36","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100838_bib37","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.lanepe.2024.100838_bib38","article-title":"Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive lung cancers","volume":"6","author":"Drilon","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.lanepe.2024.100838_bib39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.lanepe.2024.100838_bib40","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.lanepe.2024.100838_bib41","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.lanepe.2024.100838_bib42","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1242\/jcs.182873","article-title":"RAS isoforms and mutations in cancer at a glance","volume":"129","author":"Hobbs","year":"2016","journal-title":"J\u00a0Cell Sci"},{"issue":"12","key":"10.1016\/j.lanepe.2024.100838_bib43","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.3390\/cancers14122971","article-title":"A\u00a0real-world systematic analysis of driver mutations' prevalence in early- and advanced-stage NSCLC: implications for targeted therapies in the adjuvant setting","volume":"14","author":"Terrenato","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.lanepe.2024.100838_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2022.03.015","article-title":"Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study","volume":"167","author":"Garcia","year":"2022","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lanepe.2024.100838_bib45","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.cllc.2023.05.002","article-title":"KRAS G12C mutant non-small cell lung cancer linked to female sex and high risk of CNS metastasis: population-based demographics and survival data from the National Swedish Lung Cancer Registry","volume":"24","author":"Isaksson","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"11","key":"10.1016\/j.lanepe.2024.100838_bib46","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"7477","key":"10.1016\/j.lanepe.2024.100838_bib47","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.lanepe.2024.100838_bib48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery of a covalent inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"J\u00a0Med Chem"},{"issue":"25","key":"10.1016\/j.lanepe.2024.100838_bib49","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with\u00a0KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10378","key":"10.1016\/j.lanepe.2024.100838_bib50","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2024.100838_bib51","first-page":"35","article-title":"Lung cancer with MET exon 14 skipping mutation: genetic feature, current treatments, and future challenges","volume":"12","author":"Fujino","year":"2021","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.lanepe.2024.100838_bib52","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100838_bib53","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jtho.2022.10.015","article-title":"MET alterations in NSCLC-current perspectives and future challenges","volume":"18","author":"Remon","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"issue":"10","key":"10.1016\/j.lanepe.2024.100838_bib54","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.lanepe.2024.100838_bib55","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 4","key":"10.1016\/j.lanepe.2024.100838_bib56","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lanepe.2024.100838_bib58","series-title":"Lung cancer: diagnosis and management (NICE guideline [NG122])","year":"2023"},{"issue":"9","key":"10.1016\/j.lanepe.2024.100838_bib59","doi-asserted-by":"crossref","first-page":"677","DOI":"10.20344\/amp.17680","article-title":"Portuguese consensus recommendations for next-generation sequencing of lung cancer, rare tumors, and cancers of unknown primary origin in clinical practice","volume":"35","author":"Teixeira","year":"2022","journal-title":"Acta Med Port"},{"issue":"1","key":"10.1016\/j.lanepe.2024.100838_bib60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12254-019-00565-0","article-title":"The 2020 update of the recommendations of the Austrian working group on lung pathology and oncology for the diagnostic workup of non-small cell lung cancer with focus on predictive biomarkers","volume":"13","author":"Popper","year":"2020","journal-title":"Memo"},{"key":"10.1016\/j.lanepe.2024.100838_bib61","series-title":"PORO\u010cILO BOLNI\u0160NI\u010cNEGA REGISTRA TUMORJEV PRSNEGA KO\u0160A KLINIKE GOLNIK ZA LETA 2010 \u2013 2020","author":"Jan\u017ei\u010d","year":"2022"},{"key":"10.1016\/j.lanepe.2024.100838_bib63","series-title":"Lungenkarzinom, nicht-kleinzellig (NSCLC)","author":"Griesinger","year":"2022"},{"key":"10.1016\/j.lanepe.2024.100838_bib64","series-title":"Patients atteints d'un cancer bronchique non \u00e0 petites cellules: indications des tests mol\u00e9culaires en vue de la prescription de traitements de pr\u00e9cision","year":"2023"},{"key":"10.1016\/j.lanepe.2024.100838_bib65","series-title":"Federatie Medisch Specialisten (FMS) - Richtlijn Niet-kleincellig longcarcinoom","year":"2020"},{"key":"10.1016\/j.lanepe.2024.100838_bib66","series-title":"Lungcancer - Nationellt v\u00e5rdprogram (v7.0)","year":"2023"},{"issue":"2","key":"10.1016\/j.lanepe.2024.100838_bib67","first-page":"97","article-title":"[New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology]","volume":"56","author":"Isla","year":"2023","journal-title":"Rev Esp Patol"},{"key":"10.1016\/j.lanepe.2024.100838_bib68","series-title":"Dire\u00e7\u00e3o-Geral da Sa\u00fade (DGS) - Diagn\u00f3stico e Tratamento do Carcinoma de N\u00e3o Pequenas C\u00e9lulas do Pulm\u00e3o","year":"2013"},{"issue":"25","key":"10.1016\/j.lanepe.2024.100838_bib69","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1200\/JCO.20.03307","article-title":"Clinicopathologic features and response to therapy of NRG1 fusion-driven lung cancers: the eNRGy1 global multicenter registry","volume":"39","author":"Drilon","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.lanepe.2024.100838_bib70","doi-asserted-by":"crossref","DOI":"10.1177\/1179554920950548","article-title":"Results of the Austrian national lung cancer audit","volume":"14","author":"Burghuber","year":"2020","journal-title":"Clin Med Insights Oncol"},{"issue":"6","key":"10.1016\/j.lanepe.2024.100838_bib71","article-title":"Biomarker testing for people with advanced lung cancer in England","volume":"2","author":"Adizie","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"1","key":"10.1016\/j.lanepe.2024.100838_bib72","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/cancers14010092","article-title":"Biomarker testing in older patients treated for an advanced or metastatic non-squamous non-small-cell lung cancer: the French ESME real-life multicenter cohort experience","volume":"14","author":"Lamy","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.lanepe.2024.100838_bib73","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2020.10.012","article-title":"Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)","volume":"152","author":"Griesinger","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lanepe.2024.100838_bib74","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.lungcan.2022.04.001","article-title":"Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice","volume":"167","author":"Steeghs","year":"2022","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.lanepe.2024.100838_bib75","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jclinpath-2020-207280","article-title":"Real-world biomarker testing rate and positivity rate in NSCLC in Spain: prospective central lung cancer biomarker testing registry (LungPath) from the Spanish Society of Pathology (SEAP)","volume":"75","author":"Salas","year":"2022","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.lanepe.2024.100838_bib76","article-title":"[National variation in molecular diagnostics in metastatic lung cancer]","volume":"162","author":"Kuijpers","year":"2018","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"5","key":"10.1016\/j.lanepe.2024.100838_bib77","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/cancers15051505","article-title":"Real-world data on EGFR and ALK testing and TKI usage in Norway-a nation-wide population study","volume":"15","author":"Eide","year":"2023","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.lanepe.2024.100838_bib78","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1093\/oncolo\/oyad134","article-title":"Variations in genomic testing in non-small cell lung carcinoma: a healthcare professional survey of current practices in the UK","volume":"28","author":"Baijal","year":"2023","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.lanepe.2024.100838_bib79","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.chest.2021.06.027","article-title":"Knowledge and practice patterns among pulmonologists for molecular biomarker testing in\u00a0advanced non-small cell lung cancer","volume":"160","author":"Fox","year":"2021","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100838_bib80","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10809","article-title":"Practice-level variation in molecular testing and use of targeted therapy for patients with non-small cell lung cancer and colorectal cancer","volume":"6","author":"Roberts","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.lanepe.2024.100838_bib81","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.clon.2022.08.025","article-title":"Implementing genomic testing for lung cancer into routine clinical practice - the Welsh experience","volume":"34","author":"Cox","year":"2022","journal-title":"Clin Oncol"},{"key":"10.1016\/j.lanepe.2024.100838_bib82","first-page":"70","article-title":"Optimalisatie van\u00a0de zorgketen moleculaire diagnostiek bij niet-kleincellig longcarcinoom in Noord-Nederland","volume":"20","author":"de Jager","year":"2023","journal-title":"Ned Tijdschr Oncol"},{"issue":"11","key":"10.1016\/j.lanepe.2024.100838_bib83","doi-asserted-by":"crossref","first-page":"e1874","DOI":"10.1200\/OP.22.00260","article-title":"Improving time to molecular testing results in patients with newly diagnosed, metastatic non-small-cell lung cancer","volume":"18","author":"Ossowski","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.lanepe.2024.100838_bib84","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.lungcan.2022.08.003","article-title":"Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: a UK expert consensus statement","volume":"172","author":"Navani","year":"2022","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lanepe.2024.100838_bib85","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00428-016-2025-7","article-title":"Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL","volume":"470","author":"Deans","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.lanepe.2024.100838_bib86","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1200\/PO.20.00008","article-title":"Relevance and effectiveness of molecular tumor board recommendations for patients with non-small-cell lung cancer with rare or complex mutational profiles","volume":"4","author":"Koopman","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"10.1016\/j.lanepe.2024.100838_bib87","doi-asserted-by":"crossref","first-page":"e1347","DOI":"10.1002\/onco.13580","article-title":"Multicenter comparison of molecular tumor boards in the Netherlands: definition, composition, methods, and targeted therapy recommendations","volume":"26","author":"Koopman","year":"2021","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100838_bib88","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/joim.13698","article-title":"Implementation of precision medicine in healthcare-a European perspective","volume":"294","author":"Stenzinger","year":"2023","journal-title":"J\u00a0Intern Med"},{"issue":"5","key":"10.1016\/j.lanepe.2024.100838_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101628","article-title":"Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe","volume":"8","author":"Hofman","year":"2023","journal-title":"ESMO Open"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776224000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776224000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:58:35Z","timestamp":1731499115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776224000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":87,"alternative-id":["S2666776224000048"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100838","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100841","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100845","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100840","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100839","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100838"}}